5′-Cap Modified RNA for Vaccine Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
RNA-based vaccines face instability issues in vivo, particularly in immune cells, leading to short half-life and low protein expression, which limits their effectiveness in vaccination and gene therapy.
Innovation Solution
Modification of RNA with a 5′-cap structure, specifically a phosphorothioate 5′-cap analog, to enhance stability and translation efficiency in immature antigen-presenting cells, thereby increasing immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If RNA is used for vaccination, then transient expression and non-transforming character are achieved, but stability in vivo is poor leading to short half-life
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the 5'-cap analog. Specifically, it uses a phosphorothioate bond (replacing one oxygen atom with sulfur) and an ARCA (anti-reverse cap analog) structure with a 2'-O-methyl ribose and phosphorothioate linkage. These structural parameter changes significantly increase RNA stability by protecting against nuclease degradation while maintaining translation efficiency, thereby resolving the contradiction between safety and half-life.
Solution Approach 2:
The patent employs a composite cap structure combining multiple functional elements: the 7-methylguanosine base, the phosphorothioate linkage, the 2'-O-methyl ribose, and the ARCA design. This composite structure integrates protection against decapping enzymes, resistance to nucleases, and maintained affinity for translation initiation factors, achieving both extended half-life and sustained safety profile.
2Reliability
If RNA is used for vaccination, then non-transforming character is achieved, but protein expression is low due to degradation
Solution Approach 1:
The patent modifies the 5'-cap structure parameters to include a phosphorothioate bond and ARCA design, which protect the RNA from degradation while maintaining its ability to be translated. This resolves the contradiction by preserving the non-transforming character of RNA while significantly enhancing protein expression through increased stability and reduced degradation.
Solution Approach 2:
The patent converts the inherent vulnerability of RNA (susceptibility to nuclease degradation) into a benefit by using the phosphorothioate modification. The sulfur atom in the phosphorothioate bond provides steric protection and chemical stability, transforming RNA's weakness into enhanced durability and sustained protein expression without altering its non-transforming nature.
3Productivity
If conventional 5'-cap is used, then translation initiation is supported, but RNA is rapidly degraded by decapping enzymes
Solution Approach 1:
The patent changes the chemical parameters of the 5'-cap by introducing a phosphorothioate bond and ARCA structure. These modifications alter the cap's resistance to decapping enzymes while preserving its ability to bind eukaryotic translation initiation factors. The phosphorothioate linkage provides steric protection against decapping enzymes, and the ARCA design maintains translation initiation efficiency, thus resolving the contradiction between translation support and decapping resistance.
4Duration of action of stationary object
If RNA stability is increased through modification, then half-life is extended, but complexity of modification increases
Solution Approach 1:
The patent applies parameter changes to the 5'-cap structure by incorporating a phosphorothioate bond and ARCA design elements. While these modifications do increase structural complexity, they achieve substantial half-life extension through a well-defined chemical approach. The modification complexity is managed by using established chemical synthesis methods for phosphorothioate bonds and standardized ARCA building blocks, making the increased complexity worthwhile given the dramatic improvement in stability.
Data Source
AI summary
The present invention relates to modification of RNA with 5′-cap analogs of Formula (1):wherein R1-R6 and n are as described herein, in order to improve the stability and increase the expression of said RNA, in particular in immature antigen presenting cells. The present invention provides a vaccine composition comprising said stabilized RNA, immature antigen presenting cells comprising said stabilized RNA, and methods for stimulating and/or activating immune effector cells and for inducing an immune response in an individual using said stabilized RNA.